Image Credit: CDC
As the COVID-19 outbreak continues to evolve, comparisons have been drawn to influenza. Both cause respiratory disease, yet there are important differences between the two viruses and how they spread. This has important implications for the public health measures that can be implemented to respond to each virus.
Q. How are COVID-19 and influenza viruses similar?
Firstly, COVID-19 and influenza viruses have a similar disease presentation. That is, they both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. Secondly, both viruses are transmitted by contact, droplets and fomites. As a result, the same public health measures, such as hand hygiene and good respiratory etiquette (coughing into your elbow or into a tissue and immediately disposing of the tissue), are important actions all can take to prevent infection.
Q. How are COVID-19 and influenza viruses different?
The speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) and a shorter serial interval (the time between successive cases) than COVID-19 virus. The serial interval for COVID-19 virus is estimated to be 5-6 days, while for influenza virus, the serial interval is 3 days. This means that influenza can spread faster than COVID19.
Further, transmission in the first 3-5 days of illness, or potentially pre-symptomatic transmission –transmission of the virus before the appearance of symptoms – is a major driver of transmission for influenza. In contrast, while we are learning that there are people who can shed COVID-19 virus 24-48 hours prior to symptom onset, at present, this does not appear to be a major driver of transmission.
The reproductive number – the number of secondary infections generated from one infected individual – is understood to be between 2 and 2.5 for COVID-19 virus, higher than for influenza. However, estimates for both COVID-19 and influenza viruses are very context and time-specific, making direct comparisons more difficult.
Children are important drivers of influenza virus transmission in the community. For COVID-19 virus, initial data indicates that children are less affected than adults and that clinical attack rates in the 0-19 age group are low.
Further preliminary data from household transmission studies in China suggest that children are infected from adults, rather than vice versa.
While the range of symptoms for the two viruses is similar, the fraction with severe disease appears to be different.
For COVID-19, data to date suggest that 80% of infections are mild or asymptomatic, 15% are severe infection, requiring oxygen and 5% are critical infections, requiring ventilation. These fractions of severe and critical infection would be higher than what is observed for influenza infection.
Those most at risk for severe influenza infection are children, pregnant women, elderly, those with underlying chronic medical conditions and those who are immunosuppressed. For COVID-19, our current understanding is that older age and underlying conditions increase the risk for severe infection.
Mortality for COVID-19 appears higher than for influenza, especially seasonal influenza. While the true mortality of COVID-19 will take some time to fully understand, the data we have so far indicate that the crude mortality ratio (the number of reported deaths divided by the reported cases) is between 3-4%, the infection mortality rate (the number of reported deaths divided by the number of infections) will be lower. For seasonal influenza, mortality is usually well below 0.1%. However, mortality is to a large extent determined by access to and quality of health care.
Q. What medical interventions are available for COVID-19 and influenza viruses?
While there are a number of therapeutics currently in clinical trials in China and more than 20 vaccines in development for COVID-19, there are currently no licensed vaccines or therapeutics for COVID-19. In contrast, antivirals and vaccines available for influenza. While the influenza vaccine is not effective against COVID-19 virus, it is highly recommended to get vaccinated each year to prevent influenza infection.
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Case classifications are based on WHO case definitions for COVID-19.
Transmission classification is based on WHO analysis of available official data and may be subject to reclassification as additional data become available. Countries/territories/areas experiencing multiple types of transmission are classified in the highest category for which there is evidence; they may be removed from a given category if interruption of transmission can be demonstrated. It should be noted that even within categories, different countries/territories/areas may have differing degrees of transmission as indicated by the differing numbers of cases and other factors. Not all locations within a given country/territory/area are equally affected.
- Community transmission is evidenced by the inability to relate confirmed cases through chains of transmission for a large number of cases, or by increasing positive tests through sentinel samples (routine systematic testing of respiratory samples from established laboratories).
- Local transmission indicates locations where the source of infection is within the reporting location.
- Imported cases only indicates locations where all cases have been acquired outside the location of reporting.
- Under investigation indicates locations where type of transmission has not been determined for any cases.
- Interrupted transmission indicates locations where interruption of transmission has been demonstrated (details to be determined)
“Territories” include territories, areas, overseas dependencies and other jurisdictions of similar status.
What you think?
Conseguir su primera perforacion de la nariz es duro, ¡especialmente cuando se necesita obtener su aprobación de sus padres! Tanto si uno está en la escuela secundaria o casada con hijos, la aprobación de los padres acerca de las cosas significa mucho para ellos.
Puede ser de gran ayuda el saber más sobre los problemas del piercing de nariz antes o después de hacerse un piercing.
Nuestras preguntas frecuentes sobre el piercing de nariz le ayudaran a encontrar una respuesta a las preguntas más comunes y acuciantes. ¿No encuentra lo que busca? Pregunte aquí.
¡Todas los detalles esenciales referentes al piercing de nariz que necesita saber! ¡Se sorprendería al saber cuántas personas todavía lo hacen incorrectamente!
Unos cuántos consejos que le ayudarán a reducir el tiempo que tarda el piercing de nariz en curarse completamente.
Tratando su infección del piercing de nariz – la prevención es el mejor tratamiento, pero ¿qué debe hacer si ya tiene la infección?
El Piercing del Tabique Nasal – La mayoría piensan que los piercings del tabique son un poco más atrevidos que simplemente una gema adornando el ala de la nariz. Algunas cosas a tener en cuenta.
Un repaso a la historia del piercing de nariz
ノーズピアス 受け継がれる歴史 ノーズピアスの歴史をもっと知りたいですよね？最古のノーズピアス、そしてインド最古のサンスクリット語の聖典「ヴェーダ」にも登場する男性・女性が使用するノーズリングについてお話をします。
This Coronavirus pages are intended solely to inform our clients and online visitors about coronavirus/COvid-19. All facts are from reliable sources like WHO, CDC and respective Government Health Agencies. Readers can either read through the facts which we summarized in this page or go direct to source through the link listed at the bottom of each page.
Subscribe to our nose-piercings newsletter to stay up-to-date with the latest news, trends and articles published on this site.